These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32787864)

  • 1. When to call it off: defining transplant candidacy limits in liver donor liver transplantation for hepatocellular carcinoma.
    Bhatti ABH; Qureshi AI; Tahir R; Dar FS; Khan NY; Zia HH; Riyaz S; Rana A
    BMC Cancer; 2020 Aug; 20(1):754. PubMed ID: 32787864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Younger age and presence of macrovascular invasion were independent significant factors associated with poor disease-free survival in hepatocellular carcinoma patients undergoing living donor liver transplantation.
    Wai CT; Woon WA; Tan YM; Lee KH; Tan KC
    Transplant Proc; 2012 Mar; 44(2):516-9. PubMed ID: 22410059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
    Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
    World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW; Yi NJ; Suh KS
    Transplantation; 2014 Apr; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors affecting recurrence and survival after living donor liver transplantation for hepatocellular carcinoma.
    Abdel-Wahab M; Sultan AM; Fathy OM; Salah T; Elshobary MM; Elghawalby NA; Yassen AM; Elsarraf WM; Elsaadany MF; Zalatah K
    Hepatogastroenterology; 2013; 60(128):1847-53. PubMed ID: 24719918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
    Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
    J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
    Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
    Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Living donor liver transplantation for advanced hepatocellular carcinoma including macrovascular invasion.
    Bhatti ABH; Naqvi W; Khan NY; Zia HH; Dar FS; Khan ZA; Rana A
    J Cancer Res Clin Oncol; 2022 Jan; 148(1):245-253. PubMed ID: 34117916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
    Jiang L; Liao A; Yan L; Li B; Zhu W; Wen T
    Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of loco regional treatments before living donor liver transplantation on overall survival and recurrence-free survival in South Korean patients with hepatocellular carcinoma.
    Na GH; Kim EY; Hong TH; You YK; Kim DG
    HPB (Oxford); 2016 Jan; 18(1):98-106. PubMed ID: 26776857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Living donor liver transplantation or hepatic resection combined with intraoperative radiofrequency ablation for Child-Pugh A hepatocellular carcinoma patient with Multifocal Tumours Meeting the University of California San Francisco (UCSF) criteria.
    Xu X; Pu X; Jiang L; Huang Y; Yan L; Yang J; Wen T; Li B; Wu H; Wang W
    J Cancer Res Clin Oncol; 2021 Feb; 147(2):607-618. PubMed ID: 32852635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria.
    Bhangui P; Saigal S; Gautam D; Piplani T; Choudhary N; Chaudhary R; Yadav S; Thiagarajan S; Rastogi A; Saraf N; Nundy S; Soin AS
    Liver Transpl; 2021 Feb; 27(2):209-221. PubMed ID: 33253492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of morphologic criteria and α-fetoprotein in selection of patients with hepatocellular carcinoma for liver transplantation minimizes the problem of posttransplant tumor recurrence.
    Grąt M; Kornasiewicz O; Lewandowski Z; Hołówko W; Grąt K; Kobryń K; Patkowski W; Zieniewicz K; Krawczyk M
    World J Surg; 2014 Oct; 38(10):2698-707. PubMed ID: 24858191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
    Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
    Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
    Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
    United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Patients With Hepatocellular Carcinomas That Do Not Produce α-Fetoprotein.
    Agopian VG; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Cheng EY; Yersiz H; Farmer DG; Hiatt JR; Busuttil RW
    JAMA Surg; 2017 Jan; 152(1):55-64. PubMed ID: 27706479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
    Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
    Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Living-donor liver transplantation associated with higher incidence of hepatocellular carcinoma recurrence than deceased-donor liver transplantation.
    Park MS; Lee KW; Suh SW; You T; Choi Y; Kim H; Hong G; Yi NJ; Kwon CH; Joh JW; Lee SK; Suh KS
    Transplantation; 2014 Jan; 97(1):71-7. PubMed ID: 24056623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of the risk factors of untransplantable recurrence after primary curative resection for patients with hepatocellular carcinoma.
    Ho CM; Wu CY; Lee PH; Lai HS; Ho MC; Wu YM; Hu RH
    Ann Surg Oncol; 2013 Aug; 20(8):2526-33. PubMed ID: 23504121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.